Inventor · disambiguated record
Rene Holm
Also filed as: HOLM RENE · HOLM RENÉ
11 granted patents·17 pending applications·204 citations·filing 2007–2025
91Inventor score
Files withLUNDBECK & CO AS H9JANSSEN PHARMACEUTICA NV7H LUNDBECK AS6ACTELION PHARMACEUTICALS LTD2JANSSEN SCIENCES IRELAND UNLIMITED CO2
Top patents by PatentIndex Score
28 records- 0194US8969355B21-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairmentLUNDBECK & CO AS H·Filed 2014·Granted Mar 3, 2015·15 cites·7 claims
- 0294US8722684B21-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairmentBANG-ANDERSEN BENNY·Filed 2007·Granted May 13, 2014·31 cites·8 claims
- 0392US9125908B21-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairmentLUNDBECK & CO AS H·Filed 2014·Granted Sep 8, 2015·11 cites·10 claims
- 0491US9227946B21-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairmentLUNDBECK & CO AS H·Filed 2014·Granted Jan 5, 2016·9 cites·5 claims
- 0591US9125909B21-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairmentLUNDBECK & CO AS H·Filed 2014·Granted Sep 8, 2015·9 cites·11 claims
- 0690US9861630B11-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairmentH LUNDBECK AS·Filed 2017·Granted Jan 9, 2018·5 cites·16 claims
- 0790US9610287B2Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophreniaHOLM RENÉ·Filed 2012·Granted Apr 4, 2017·124 cites·7 claims
- 0883US2023021520A11-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairmentH LUNDBECK AS·Filed 2022·Application pending·0 cites
- 0973US11458134B21-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairmentH LUNDBECK AS·Filed 2019·Granted Oct 4, 2022·0 cites·10 claims
- 1068US2018333408A11-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairmentH LUNDBECK AS·Filed 2017·Application pending·0 cites
- 1166US2024216366A1Pharmaceutical composition comprising a diphenylpyrazine derivativeACTELION PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 1264US12201690B2Formulations/compositions comprising ibrutinibJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Jan 21, 2025·0 cites·12 claims
- 1362US11279682B2Vortioxetine pyroglutamateH LUNDBECK AS·Filed 2019·Granted Mar 22, 2022·0 cites·10 claims
- 1459US2016083359A11-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENTLUNDBECK & CO AS H·Filed 2015·Application pending·0 cites
- 1558US2024091223A1Pharmaceutical composition comprising a diphenylpyrazine derivativeACTELION PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1656US2023355606A1Long-acting formulationsJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 1755US2023405094A1Treatment or prevention of a disease or disorderJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2021·Application pending·0 cites
- 1853US2025161456A1Formulation/compositions comprising ibrutinibJANSSEN PHARMACEUTICA NV·Filed 2025·Application pending·0 cites
- 1952US2023405001A1Treatment or prevention of hiv infectionJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2021·Application pending·0 cites
- 2050US2009306092A1Method for treating cognitive deficitsLUNDBECK & CO AS H·Filed 2009·Application pending·0 cites
- 2150US2023310413A1Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acidJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 2249US2023241051A1Long-acting formulationsJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 2349US2024277614A1Long-acting formulationsJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 2446US10287261B2Vortioxetine pyroglutamateH LUNDBECK AS·Filed 2016·Granted May 14, 2019·0 cites·12 claims
- 2546US2022175760A1Pharmaceutical formulationsJANSSEN PHARMACEUTICA NV·Filed 2020·Application pending·0 cites
- 2644US2011178094A1Oral FormulationLUNDBECK & CO AS H·Filed 2009·Application pending·0 cites
- 2743US2009143335A1Modified absorption formulation of gaboxadolLUNDBECK & CO AS H·Filed 2008·Application pending·0 cites
- 2837US2011207744A1Method for treating cognitive deficitsLUNDBECK & CO AS H·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →